Twelve peptides removed from FDA Category 2. PCAC public meeting July 23–24, 2026. State boards continue to fill in around the federal floor. This is the first edition of PPA's Monthly Regulatory Currency Tracker. Every month, this digest reports what the FDA, DEA, state pharmacy boards, and major clinical bodies are saying about peptide therapy, with primary sources cited for every item. Educational only. Not legal or medical advice. The April 2026 drop is the largest single regulatory event since the September 2024 Category 2 nominator withdrawals. Review it before your next prescription. Verify with your compounding pharmacy. Document the regulatory status in the chart note. —— What's in this edition • Q1 2026 catch-up. January through March 2026 in three pages, for prescribers joining mid-year. • Section 1. FDA 503A bulks list. Twelve peptides removed from Category 2 on April 15, 2026; PCAC public meeting July 23–24, 2026. • Section 2. FDA enforcement. Thirty warning letters to telehealth GLP-1 marketers (March 3); Gram Peptides Research Use Only warning letter (March 31); 503A and 503B exemption reminder (April 1). • Section 3. DEA scheduling and telemedicine. No new federal peptide scheduling in April. Controlled-substance telemedicine flexibility extended through December 31, 2026. • Section 4. State pharmacy boards. California, Texas, Florida, New York, Arizona, plus the next five top states. California's June 2025 Essentially a Copy rule remains the active enforcement vector. • Section 5. Clinical guidance. A4M Peptide Therapy Certification curriculum continues. AACE, AAPS, and ISPRM positions tracked. • Section 6. Telehealth. Federal posture, state posture, what's coming. • Section 7. Notable research. Retatrutide TRIUMPH-4 (December 2025). NEJM SURMOUNT-5 tirzepatide vs. semaglutide head-to-head (2025). • Per-peptide regulatory status table. All 28 peptides covered in the PPA curriculum, in one snapshot. • Upcoming dockets and dates to watch.